Hao Wang, Kristin N Berger, Elizabeth L Miller, Wei Fu, Larisa Broglie, Frederick D Goldman, Heiko Konig, Su Jin Lim, Arthur S Berg, Julie-An Talano, Melanie A Comito, Sherif S Farag, Jeffrey J Pu
{"title":"全身照射对脐带血造血干细胞移植的影响。","authors":"Hao Wang, Kristin N Berger, Elizabeth L Miller, Wei Fu, Larisa Broglie, Frederick D Goldman, Heiko Konig, Su Jin Lim, Arthur S Berg, Julie-An Talano, Melanie A Comito, Sherif S Farag, Jeffrey J Pu","doi":"10.1177/20406207231170708","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Umbilical cord blood hematopoietic stem cells are commonly used for hematopoietic system reconstitution in recipients after umbilical cord blood transplantation (UCBT). However, the optimal conditioning regimen for UCBT remains a topic of debate. The exact impact of total body irradiation (TBI) as a part of conditioning regimens remains unknown.</p><p><strong>Objectives: </strong>The aim of this study was to evaluate the impacts of TBI on UCBT outcomes.</p><p><strong>Design: </strong>This was a multi-institution retrospective study.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the outcomes of 136 patients receiving UCBT. Sixty-nine patients received myeloablative conditioning (MAC), in which 33 underwent TBI and 36 did not, and 67 patients received reduced-intensity conditioning (RIC), in which 43 underwent TBI and 24 did not. Univariate and multivariate analyses were conducted to compare the outcomes and the post-transplant complications between patients who did and did not undergo TBI in the MAC subgroup and RIC subgroup, respectively.</p><p><strong>Results: </strong>In the RIC subgroup, patients who underwent TBI had superior overall survival (adjusted hazard ratio [aHR] = 0.25, 95% confidence interval [CI]: 0.09-0.66, p = 0.005) and progression-free survival (aHR = 0.26, 95% CI: 0.10-0.66, p = 0.005). However, in the MAC subgroup, there were no statistically significant differences between those receiving and not receiving TBI.</p><p><strong>Conclusion: </strong>In the setting of RIC in UCBT, TBI utilization can improve overall survival and progression-free survival. However, TBI does not show superiority in the MAC setting.</p>","PeriodicalId":23048,"journal":{"name":"Therapeutic Advances in Hematology","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/03/0e/10.1177_20406207231170708.PMC10161310.pdf","citationCount":"0","resultStr":"{\"title\":\"The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation.\",\"authors\":\"Hao Wang, Kristin N Berger, Elizabeth L Miller, Wei Fu, Larisa Broglie, Frederick D Goldman, Heiko Konig, Su Jin Lim, Arthur S Berg, Julie-An Talano, Melanie A Comito, Sherif S Farag, Jeffrey J Pu\",\"doi\":\"10.1177/20406207231170708\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Umbilical cord blood hematopoietic stem cells are commonly used for hematopoietic system reconstitution in recipients after umbilical cord blood transplantation (UCBT). However, the optimal conditioning regimen for UCBT remains a topic of debate. The exact impact of total body irradiation (TBI) as a part of conditioning regimens remains unknown.</p><p><strong>Objectives: </strong>The aim of this study was to evaluate the impacts of TBI on UCBT outcomes.</p><p><strong>Design: </strong>This was a multi-institution retrospective study.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the outcomes of 136 patients receiving UCBT. Sixty-nine patients received myeloablative conditioning (MAC), in which 33 underwent TBI and 36 did not, and 67 patients received reduced-intensity conditioning (RIC), in which 43 underwent TBI and 24 did not. Univariate and multivariate analyses were conducted to compare the outcomes and the post-transplant complications between patients who did and did not undergo TBI in the MAC subgroup and RIC subgroup, respectively.</p><p><strong>Results: </strong>In the RIC subgroup, patients who underwent TBI had superior overall survival (adjusted hazard ratio [aHR] = 0.25, 95% confidence interval [CI]: 0.09-0.66, p = 0.005) and progression-free survival (aHR = 0.26, 95% CI: 0.10-0.66, p = 0.005). However, in the MAC subgroup, there were no statistically significant differences between those receiving and not receiving TBI.</p><p><strong>Conclusion: </strong>In the setting of RIC in UCBT, TBI utilization can improve overall survival and progression-free survival. However, TBI does not show superiority in the MAC setting.</p>\",\"PeriodicalId\":23048,\"journal\":{\"name\":\"Therapeutic Advances in Hematology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/03/0e/10.1177_20406207231170708.PMC10161310.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/20406207231170708\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20406207231170708","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:脐带血造血干细胞常用于脐带血移植(UCBT)后受者的造血系统重建。然而,UCBT的最佳调理方案仍然是一个有争议的话题。作为调理方案的一部分,全身照射(TBI)的确切影响尚不清楚。目的:本研究的目的是评估脑外伤对UCBT结果的影响。设计:这是一项多机构回顾性研究。方法:对136例接受UCBT治疗的患者进行回顾性分析。69例患者接受了清髓调节(MAC),其中33例接受了TBI, 36例未接受TBI; 67例患者接受了降低强度调节(RIC),其中43例接受了TBI, 24例未接受TBI。进行单因素和多因素分析,分别比较MAC亚组和RIC亚组中接受和未接受TBI的患者的结局和移植后并发症。结果:在RIC亚组中,接受TBI的患者总体生存期(校正风险比[aHR] = 0.25, 95%可信区间[CI]: 0.09-0.66, p = 0.005)和无进展生存期(aHR = 0.26, 95% CI: 0.10-0.66, p = 0.005)更优等。然而,在MAC亚组中,接受和未接受TBI的患者之间没有统计学上的显著差异。结论:在UCBT的RIC设置中,TBI的使用可以提高总生存期和无进展生存期。然而,TBI在MAC设置中并没有表现出优势。
The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation.
Background: Umbilical cord blood hematopoietic stem cells are commonly used for hematopoietic system reconstitution in recipients after umbilical cord blood transplantation (UCBT). However, the optimal conditioning regimen for UCBT remains a topic of debate. The exact impact of total body irradiation (TBI) as a part of conditioning regimens remains unknown.
Objectives: The aim of this study was to evaluate the impacts of TBI on UCBT outcomes.
Design: This was a multi-institution retrospective study.
Methods: A retrospective analysis was conducted on the outcomes of 136 patients receiving UCBT. Sixty-nine patients received myeloablative conditioning (MAC), in which 33 underwent TBI and 36 did not, and 67 patients received reduced-intensity conditioning (RIC), in which 43 underwent TBI and 24 did not. Univariate and multivariate analyses were conducted to compare the outcomes and the post-transplant complications between patients who did and did not undergo TBI in the MAC subgroup and RIC subgroup, respectively.
Results: In the RIC subgroup, patients who underwent TBI had superior overall survival (adjusted hazard ratio [aHR] = 0.25, 95% confidence interval [CI]: 0.09-0.66, p = 0.005) and progression-free survival (aHR = 0.26, 95% CI: 0.10-0.66, p = 0.005). However, in the MAC subgroup, there were no statistically significant differences between those receiving and not receiving TBI.
Conclusion: In the setting of RIC in UCBT, TBI utilization can improve overall survival and progression-free survival. However, TBI does not show superiority in the MAC setting.
期刊介绍:
Therapeutic Advances in Hematology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of hematology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in hematology, providing a forum in print and online for publishing the highest quality articles in this area.